REFERENCE FILE
Bremelanotide
Examine the reference details alongside the questions and dated sources.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- Melanocortin-receptor agonist.
- Evidence
- Randomized trials.
- Limitations
- Exclude medical, relationship and drug causes; not performance enhancement.
- Safety
- Uncontrolled hypertension or known cardiovascular disease: contraindicated.
- Formulation and route
- Subcutaneous injection.
- Approval scope
- Vyleesi: eligible premenopausal women with distressing acquired generalized low-desire disorder.
READING NOTES
Questions for a closer look
For a bremelanotide estimate, write a boundary statement naming the circumstances to which your intended interpretation refers. Check that statement against the source's population, measurement conditions and period of observation. Change one circumstance in an explicitly hypothetical application and ask which supporting connection must now be established. Repeat with a different circumstance, keeping the questions separate. Do not assign an invented correction to the estimate when a connection is unresolved. The useful product is a set of conditional statements: the interpretation extends to the new setting only if the specified connections can be justified with relevant evidence.
Questions to investigate
- Which circumstances define the application I want the estimate to support?
- What connection needs checking when I change one circumstance hypothetically?
- What evidence would justify that extension without inventing a numerical correction?
Sources for this file
- VYLEESINLM · Checked
- Kingsberg trialsPubMed · Checked
MED CONSUMER WATCH · RESEARCH
Read the evidence behind the question.
Browse reference files or follow a study analysis from its question to its limitations.